Development of Neoantigens: From Identification in Cancer Cells to Application in Cancer Vaccines Publisher Pubmed



Ebrahimi N¹ ; Akbari M² ; Ghanaatian M³ ; Roozbahani Moghaddam P⁴ ; Adelian S⁵ ; Borjian Boroujeni M⁶ ; Yazdani E⁷ ; Ahmadi A⁸ ; Hamblin MR⁹ Show Affiliations
Source: Expert Review of Vaccines Published:2022

Abstract

Introduction: The discovery of neoantigens as mutated proteins specifically expressed in tumor cells but not in normal cells has led to improved cancer vaccines. Targeting neoantigens can induce anti-tumor T-cell responses to destroy tumors without damaging healthy cells. Extensive advances in genome sequencing technology and bioinformatics analysis have made it possible to discover and design effective neoantigens for use in therapeutic cancer vaccines. Neoantigens-based therapeutic personalized vaccines have shown promising results in cancer immunotherapy. Areas covered: We discuss the types of cancer neoantigens that can be recognized by the immune system in this review. We also summarize the detection, identification, and design of neoantigens and their appliction in developing cancer vaccines. Finally, clinical trials of neoantigen-based vaccines, their advantages, and their limitations are reviewed. From 2015 to 2020, the authors conducted a literature search of controlled randomized trials and laboratory investigations that that focused on neoantigens, their use in the design of various types of cancer vaccines. Expert opinion: Neoantigens are cancer cell-specific antigens, which their expression leads to the immune stimulation against tumor cells. The identification and delivery of specific neoantigens to antigen-presenting cells (APCs) with the help of anti-cancer vaccines promise novel and more effective cancer treatments. © 2021 Informa UK Limited, trading as Taylor & Francis Group.